New blood test could spot dangerous prostate cancer without a biopsy
NCT ID NCT07492927
First seen Mar 26, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This study is testing a new blood test that looks for genetic material from tiny particles called exosomes to diagnose aggressive prostate cancer. The goal is to see if this test can accurately identify men who need a biopsy, avoiding unnecessary procedures. Researchers plan to enroll 1700 men with elevated PSA or other signs of prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICALLY SIGNIFICANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, Ningxia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern Memorial Hospital
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Qinghai University Affiliated Hospital
RECRUITINGXining, Qinghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shaanxi Provincial People's Hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Hospital of Lanzhou University
RECRUITINGLanzhou, Gansu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
RECRUITINGXianyang, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Weinan Central Hospital
RECRUITINGWeinan, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Xijing 986 Hospital
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xijing Hospital
RECRUITINGXi'an, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yan'an University Affiliated Hospital
RECRUITINGYan’an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
plasma exosome RNA panel (blood test)
What this could lead to
If successful, this blood test could provide a non-invasive way to diagnose aggressive prostate cancer, potentially reducing the need for invasive biopsies.
What could go wrong
This is a diagnostic study, not a treatment. The test may not be accurate enough to replace current methods, and results may not apply to all populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.